

June 15, 2017

OTC Markets Group, Inc.  
304 Hudson Street  
New York, New York 10013

**RE: DREAMLIFE TECHNOLOGY, INC., A WYOMING CORPORATION, F/K/A I BRANDS  
CORPORATION (THE "COMPANY" OR THE "ISSUER")**

Dear Sir/Madam:

On May 31, 2017, the law offices of Paesano Akkashian Apkarian, P.C., a Michigan professional corporation (the "Firm"), and more specifically, the undersigned, was retained by Dreamlife Technology, Inc., a Wyoming corporation (the "Company") to submit this opinion. The Company amended its Articles of Incorporation on June 2, 2017. The amendment changed the name of the Company pursuant to consent resolutions and amendments recommended by the Board of Directors to the shareholders and subsequently adopted by the shareholders pursuant to the applicable provisions of the Wyoming Corporation Act and Bylaws of the Company.

1. OTC Markets Group is entitled to rely on this letter in determining whether Issuer has made current information publicly available within the meaning of Rule 144(c)(2) of the Securities Act of 1933.
2. I am a resident of the United States and an attorney in good standing licensed by the State Bar of Michigan. My law firm acts as general counsel to the Issuer. This letter does not rely on the work of other counsel. This letter applies to the United States of America and all jurisdictions therein.
3. I have examined such corporate records and other documents and such questions of law as I considered necessary or appropriate for purposes of rendering this letter, including but not limited to, (a) an executed Management Representation Letter dated June 1, 2017 from James Lay - Chief Executive Officer as of April 10, 2017, (b) a Management Representation Letter dated June 15, 2017 from Michael Ogburn - Chief Executive Officer and Chief Financial Officer until April 10, 2017, (c) Consent Resolutions of the Board of Directors dated June 1, 2017 making certain recommendations to the shareholders, (d) Consent Resolutions of the Shareholders dated June 2, 2017 accepting the recommendations of the Board of Directors, and (e) corporate records produced to the undersigned by the former control party of the Company - Lightwave Capital, LLC. I have relied on these documents, and more specifically, the Management Representation Letter of Michael Ogburn in making certain factual representations in this letter since he was the chief executive and financial officer of the Company for the year ended December 31, 2016.
4. I am permitted to practice before the United States Securities and Exchange Commission (the "SEC") and have not been prohibited from practicing thereunder.
5. As to matters of fact, I have relied on information obtained from public documents, officers of the Issuer and other sources believed to be reliable. In my examination, I have assumed the genuineness of all

signatures on all documents, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as photocopies, and authenticity of the originals of such latter documents.

I have reviewed the Annual Report for the period end date of December 31, 2016; and posted May 25, 2017 and supplemented on June 7, 2017 and on June 15, 2017, all of which include the Annual Information and Disclosure Statements (the "Information"), and it is my opinion that said document is accurate, up-to-date and contains the most current information available on the Issuer based on the assumptions of accuracy set forth herein and the statements made by management.

6. The information referred to above (i) constitutes "adequate current public information" concerning the Securities and the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Securities Act, (ii) includes all the information that a broker-dealer would require to obtain from the issuer to publish a quotation for the Securities under the Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"), (iii) complies as to form with the Pink OTC Markets' Guidelines for Providing Adequate Current Information, which are located on the Internet at [www.otcm Markets.com](http://www.otcm Markets.com), and (iv) has been posted through the OTC Disclosure and News Service.

7. The person responsible for the preparation of the financial statements contained in the information is Michael Ogburn. Mr. Ogburn has represented that he worked with an independent certified public accountant in preparing the financial statements, and has represented that he has experience as a chief executive and financial officer of similarly situated companies. The financial statements have not been audited.

8. The Issuer's transfer agent is ClearTrust, LLC, located at 16540 Pointe Village Drive, Suite 210 in Lutz, Florida 33558. The transfer agent is registered with the SEC. I have confirmed the number of outstanding shares in the information by reviewing the shareholder list and speaking with the transfer agent.


9. I have (i) met with Michael Ogburn and James Lay by way of FaceTime on May 31, 2017 and June 1, 2017, respectively, and (ii) reviewed the Information published by the Issuer through the OTC Disclosure and News Service, or pursuant to the Management Representation Letter, will be reviewing the Information through future disclosures, and (iii) discussed the Information with management.

10. To the best of my knowledge, after inquiry of management, neither the Issuer, any 5% shareholder, nor counsel is under investigation by any federal, or state regulatory authority for any violation of federal or state securities laws.

11. This letter is give solely to you, and may not be released to or relied upon by, nor is it intended to benefit, any other person, any other person or for any other purpose without our prior written consent; provided, however, OTC Market Groups has full and complete permission to publish the letter through the OTC Disclosure and News Service for viewing by the public and regulators.

The Firm reserves the right to amend this letter in the event additional information is disclosed requiring a supplement to the Information, and thus this opinion.

Very truly yours,  
PAESANO AKKASHIAN APKARIAN, PC



Anthony R. Paesano

ARP/ma